A detailed history of Northern Trust Corp transactions in Alkermes Plc. stock. As of the latest transaction made, Northern Trust Corp holds 1,744,680 shares of ALKS stock, worth $51.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,744,680
Previous 1,772,751 1.58%
Holding current value
$51.7 Million
Previous $42.7 Million 14.3%
% of portfolio
0.01%
Previous 0.01%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$23.01 - $28.55 $645,913 - $801,427
-28,071 Reduced 1.58%
1,744,680 $48.8 Million
Q2 2024

Aug 14, 2024

SELL
$23.21 - $27.24 $560,916 - $658,309
-24,167 Reduced 1.34%
1,772,751 $42.7 Million
Q1 2024

May 14, 2024

SELL
$26.4 - $32.56 $1.24 Million - $1.53 Million
-46,913 Reduced 2.54%
1,796,918 $48.6 Million
Q4 2023

Feb 13, 2024

BUY
$23.37 - $28.68 $3.62 Million - $4.44 Million
154,944 Added 9.17%
1,843,831 $51.1 Million
Q3 2023

Nov 13, 2023

BUY
$27.17 - $31.97 $368,017 - $433,033
13,545 Added 0.81%
1,688,887 $47.3 Million
Q2 2023

Aug 11, 2023

BUY
$28.34 - $33.63 $1.18 Million - $1.4 Million
41,512 Added 2.54%
1,675,342 $52.4 Million
Q1 2023

May 15, 2023

BUY
$25.31 - $29.02 $478,637 - $548,797
18,911 Added 1.17%
1,633,830 $46.1 Million
Q4 2022

Feb 13, 2023

BUY
$21.94 - $26.24 $293,315 - $350,802
13,369 Added 0.83%
1,614,919 $42.2 Million
Q3 2022

Nov 14, 2022

SELL
$22.0 - $31.87 $293,238 - $424,795
-13,329 Reduced 0.83%
1,601,550 $35.8 Million
Q2 2022

Aug 12, 2022

SELL
$26.4 - $30.54 $467,359 - $540,649
-17,703 Reduced 1.08%
1,614,879 $48.1 Million
Q1 2022

May 13, 2022

SELL
$23.07 - $27.99 $1.89 Million - $2.29 Million
-81,979 Reduced 4.78%
1,632,582 $43 Million
Q4 2021

Feb 08, 2022

SELL
$21.47 - $32.08 $652,022 - $974,237
-30,369 Reduced 1.74%
1,714,561 $39.9 Million
Q3 2021

Nov 15, 2021

SELL
$23.37 - $32.13 $897,852 - $1.23 Million
-38,419 Reduced 2.15%
1,744,930 $53.8 Million
Q2 2021

Aug 13, 2021

BUY
$18.78 - $25.15 $19.3 Million - $25.8 Million
1,026,700 Added 135.69%
1,783,349 $43.7 Million
Q1 2021

May 12, 2021

BUY
$18.21 - $23.2 $326,396 - $415,836
17,924 Added 2.43%
756,649 $14.1 Million
Q4 2020

Feb 11, 2021

SELL
$15.39 - $22.1 $181,109 - $260,072
-11,768 Reduced 1.57%
738,725 $14.7 Million
Q3 2020

Nov 16, 2020

SELL
$16.16 - $20.66 $516,295 - $660,066
-31,949 Reduced 4.08%
750,493 $12.4 Million
Q2 2020

Aug 14, 2020

SELL
$13.31 - $19.41 $250,307 - $365,024
-18,806 Reduced 2.35%
782,442 $15.2 Million
Q1 2020

May 14, 2020

BUY
$13.06 - $21.24 $841,272 - $1.37 Million
64,416 Added 8.74%
801,248 $11.6 Million
Q4 2019

Feb 14, 2020

SELL
$17.29 - $21.74 $3.27 Million - $4.11 Million
-189,210 Reduced 20.43%
736,832 $15 Million
Q3 2019

Nov 13, 2019

SELL
$19.51 - $24.28 $128,785 - $160,272
-6,601 Reduced 0.71%
926,042 $18.1 Million
Q2 2019

Aug 13, 2019

BUY
$21.47 - $37.33 $310,262 - $539,455
14,451 Added 1.57%
932,643 $21 Million
Q1 2019

May 13, 2019

BUY
$28.4 - $36.49 $121,438 - $156,031
4,276 Added 0.47%
918,192 $33.5 Million
Q4 2018

Feb 12, 2019

BUY
$27.94 - $44.61 $1.63 Million - $2.61 Million
58,444 Added 6.83%
913,916 $27 Million
Q3 2018

Nov 14, 2018

SELL
$38.6 - $46.12 $792,380 - $946,751
-20,528 Reduced 2.34%
855,472 $36.3 Million
Q2 2018

Sep 18, 2018

SELL
$40.56 - $51.36 $431,639 - $546,573
-10,642 Reduced 1.2%
876,000 $36.1 Million
Q2 2018

Aug 14, 2018

BUY
$40.56 - $51.36 $1.47 Million - $1.86 Million
36,168 Added 4.25%
886,642 $36.5 Million
Q1 2018

May 09, 2018

SELL
$53.61 - $67.26 $443,837 - $556,845
-8,279 Reduced 0.96%
850,474 $49.3 Million
Q4 2017

Feb 14, 2018

BUY
$47.69 - $55.39 $21,460 - $24,925
450 Added 0.05%
858,753 $47 Million
Q3 2017

Nov 13, 2017

BUY
$49.16 - $54.45 $42.2 Million - $46.7 Million
858,303
858,303 $43.6 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.87B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.